JP3508314B2 - Liquid formulation containing vitamin C - Google Patents
Liquid formulation containing vitamin CInfo
- Publication number
- JP3508314B2 JP3508314B2 JP21069395A JP21069395A JP3508314B2 JP 3508314 B2 JP3508314 B2 JP 3508314B2 JP 21069395 A JP21069395 A JP 21069395A JP 21069395 A JP21069395 A JP 21069395A JP 3508314 B2 JP3508314 B2 JP 3508314B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- phospholipid
- fatty acid
- blending
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims description 72
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 title claims description 32
- 229930003268 Vitamin C Natural products 0.000 title claims description 32
- 235000019154 vitamin C Nutrition 0.000 title claims description 32
- 239000011718 vitamin C Substances 0.000 title claims description 32
- 239000012669 liquid formulation Substances 0.000 title description 2
- 239000000839 emulsion Substances 0.000 claims description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- -1 fatty acid ester Chemical class 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000003929 acidic solution Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000542 fatty acid esters of ascorbic acid Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は、酸性水溶液中でビタミ
ンＣが安定化された液剤に関する。TECHNICAL FIELD The present invention relates to a liquid preparation in which vitamin C is stabilized in an acidic aqueous solution.
【０００２】[0002]
【従来の技術】ビタミンＣは健康を維持するために重要
なビタミンの１つである。しかし、現代食生活の乱れな
どから食事より得られるビタミンＣの摂取量は減少の一
途をたどっており、食事以外にビタミンＣを摂取する簡
便な方法が望まれている。このビタミンＣを簡便に摂取
する手段の１つとして、ビタミンＣを配合したドリンク
剤をあげることができる。しかし、ドリンク剤は風味が
重要視される剤型であるため、風味の良いｐＨ２．０〜
５．０の酸性領域での製剤化が要求される。BACKGROUND ART Vitamin C is one of the important vitamins for maintaining good health. However, the intake of vitamin C obtained from meals is steadily decreasing due to the disturbance of modern diet, and a simple method of taking vitamin C other than meals is desired. As one of the means for easily taking vitamin C, a drink preparation containing vitamin C can be mentioned. However, since the drink formulation is a formulation in which the flavor is important, a pH of 2.0-
Formulation in the acidic range of 5.0 is required.
【０００３】また、ビタミンＣを外用剤として用いた場
合、肌の美白効果などが知られているが、ビタミンＣを
配合した外用製剤では肌によいとされる酸性領域での製
剤化が要求される。Further, when vitamin C is used as an external preparation, it is known that the whitening effect on the skin and the like are known. However, an external preparation containing vitamin C is required to be formulated in an acidic region which is considered to be good for the skin. It
【０００４】しかし、ビタミンＣは酸性領域での安定性
が良くない。そのためドリンク剤または外用剤にビタミ
ンＣを配合するためには、酸性領域でのビタミンＣの安
定化が必要とされていた。However, vitamin C has poor stability in the acidic region. Therefore, in order to mix vitamin C in a drink or an external preparation, it was necessary to stabilize vitamin C in an acidic range.
【０００５】従来、水溶液中でのビタミンＣの安定化方
法には、ピロ亜硫酸塩などの抗酸化剤を用いて安定化す
る方法（特開平６−２４７８５５号）やプロタミンなど
のタンパクを用いて安定化する方法（特開平６−２４７
８５４号）などが提案されているが、酸性領域下での安
定性は不十分であった。また、特開昭５７−１４５８７
号公報においてはアスコルビン酸の高級脂肪酸エステル
についての安定化方法が開示されているが、アスコルビ
ン酸あるいはその塩については記載されていない。Conventionally, as a method of stabilizing vitamin C in an aqueous solution, a method of stabilizing with an antioxidant such as pyrosulfite (JP-A-6-247855) or a protein such as protamine has been used. Method (JP-A-6-247)
No. 854) has been proposed, but its stability in an acidic region was insufficient. Also, JP-A-57-14587
The publication discloses a method for stabilizing higher fatty acid esters of ascorbic acid, but does not describe ascorbic acid or its salts.
【０００６】[0006]
【発明が解決しようとする課題】本発明の目的は、酸性
水溶液中においてビタミンＣが安定化された液剤を提供
することにある。An object of the present invention is to provide a liquid preparation in which vitamin C is stabilized in an acidic aqueous solution.
【０００７】[0007]
【課題を解決するための手段】本発明者らは鋭意検討の
結果、ビタミンＣを配合した酸性液剤において、ショ糖
脂肪酸エステルを配合し、乳化剤としてリン脂質を用い
た乳剤を配合した液剤では、驚くべきことにビタミンＣ
の安定性が向上されることを見いだし本発明を完成し
た。すなわち本発明は、ビタミンＣを配合した酸性液剤
において、ショ糖脂肪酸エステルを配合し、乳化剤とし
てリン脂質を用いた乳剤を配合したことを特徴とする液
剤である。The present inventors have SUMMARY OF THE INVENTION The result of extensive studies, in an acidic solution containing a combination of vitamin C, blended tio sugar fatty acid esters, in the liquid preparation formulated with emulsion using a phospholipid as an emulsifier Surprisingly vitamin C
The present invention has been completed by finding out that the stability of is improved. That is, the present invention provides a acidic solution containing a combination of vitamin C, blended tio sugar fatty acid ester is a liquid, characterized in that blended with emulsion using a phospholipid as an emulsifier.
【０００８】本発明は例えば以下のように実施すること
ができる。ショ糖脂肪酸エステル、リン脂質および必要
があれば脂溶性の物質を適当な溶剤、例えばエタノール
などに均一に分散し、水または水溶性化合物含有水溶液
に添加する。その後ホモジナイザーで１０００ｒｐｍ以
上、好ましくは５０００ｒｐｍ以上で撹拌して乳化する
ことにより乳化物を得る。得られた乳化物を水または水
溶性化合物含有水溶液に添加する。乳化物配合水溶液に
ビタミンＣを配合し、ｐＨ調節をすることにより本発明
の液剤を得ることができる。ビタミンＣは乳化物の添加
の前後何れにも配合することができる。またｐＨ調節剤
としてはクエン酸、リンゴ酸などの有機酸またはその塩
などを用いることができる。ｐＨの調節はビタミンＣの
配合後に行うのが好ましく、その時のｐＨは２．０〜
５．０が好ましい。The present invention can be implemented, for example, as follows. Sucrose fatty acid ester, phospholipid and, if necessary, fat-soluble substance are uniformly dispersed in a suitable solvent, such as ethanol, and added to water or an aqueous solution containing a water-soluble compound. Thereafter, the mixture is stirred with a homogenizer at 1000 rpm or more, preferably 5000 rpm or more to emulsify to obtain an emulsion. The obtained emulsion is added to water or an aqueous solution containing a water-soluble compound. The liquid preparation of the present invention can be obtained by adding vitamin C to the emulsion-containing aqueous solution and adjusting the pH. Vitamin C can be added before or after the addition of the emulsion. As the pH adjuster, organic acids such as citric acid and malic acid or salts thereof can be used. It is preferable to adjust the pH after blending vitamin C, and the pH at that time is 2.0 to
5.0 is preferable.
【０００９】本発明の乳化物の粒子径は、乳化物の経時
的安定性から平均５００ｎｍ以下のものが好ましく、２
００ｎｍ以下のものが特に好ましい。The particle size of the emulsion of the present invention is preferably 500 nm or less on average from the viewpoint of stability of the emulsion over time.
Those of 00 nm or less are particularly preferable.
【００１０】本発明において液剤とは医薬または食品に
通常用いられる液状の剤型、例えばドリンク剤、ローシ
ョン剤、乳剤などのことである。In the present invention, the liquid agent means a liquid dosage form usually used for medicines or foods, such as drinks, lotions and emulsions.
【００１１】ビタミンＣの濃度は水溶液１ｍｌあたり好
ましくは０．１〜７０ｍｇさらに好ましくは５〜５０ｍ
ｇ配合する濃度である。ショ糖脂肪酸エステルおよびリ
ン脂質の配合量は、乳化物が安定となる濃度であれば特
に限定する必要はないが、ショ糖脂肪酸エステルが水溶
液１ｍｌあたり０．１〜３０ｍｇ、リン脂質が水溶液１
ｍｌあたり０．１〜３０ｍｇ配合する量が好ましく、重
量比でリン脂質がショ糖脂肪酸エステルの０．０５〜
１．２倍となる量が好ましい。The concentration of vitamin C is preferably 0.1 to 70 mg, more preferably 5 to 50 m, per 1 ml of the aqueous solution.
g is the concentration to be blended. The blending amount of sucrose fatty acid ester and phospholipid is not particularly limited as long as the emulsion has a stable concentration. However, sucrose fatty acid ester is 0.1 to 30 mg per 1 ml of the aqueous solution, and phospholipid is 1 to the aqueous solution.
The amount of 0.1 to 30 mg per ml is preferable, and the weight ratio of phospholipid is 0.05 to sucrose fatty acid ester.
An amount of 1.2 times is preferable.
【００１２】本発明においてビタミンＣとは、アスコル
ビン酸またはアスコルビン酸の医薬、食品として許容さ
れる塩のことである。また、ショ糖脂肪酸エステルと
は、ショ糖と脂肪酸とのエステル化物であって、その脂
肪酸の炭素数が１２〜２２のものが好ましい。特に、Ｈ
ＬＢが１１以上の物が好ましい。具体的にはショ糖ステ
アリン酸エステル、ショ糖パルミチン酸エステル、ショ
糖オレイン酸エステル、ショ糖ラウリン酸エステル、シ
ョ糖ベヘニン酸エステル、ショ糖エルカ酸エステルなど
をあげる事ができる。In the present invention, vitamin C is ascorbic acid or a salt of ascorbic acid which is acceptable as a medicine or food. Further, the sucrose fatty acid ester is an esterified product of sucrose and a fatty acid, and the fatty acid having 12 to 22 carbon atoms is preferable. Especially, H
It is preferable that the LB is 11 or more. Specifically, sucrose stearate, sucrose palmitate, sucrose oleate, sucrose laurate, sucrose behenate, sucrose erucate and the like can be mentioned.
【００１３】また、本発明でいうリン脂質とは主にグリ
セロリン脂質のことであり、好ましくはレシチンを用い
る。特に卵黄または大豆から抽出されたレシチンが好ま
しく、場合によってはさらに精製し、またはその水素添
加物を使用することもできる。さらに、全リン脂質中の
ホスファチジルコリン含量が３０％以上のものが特に好
ましい。The phospholipid as used in the present invention is mainly glycerophospholipid, and preferably lecithin is used. In particular, lecithin extracted from egg yolk or soybean is preferable, and it may be further purified or a hydrogenated product thereof may be used in some cases. Further, those having a phosphatidylcholine content of 30% or more in the total phospholipid are particularly preferable.
【００１４】さらに、本発明では乳化物中に、脂溶性の
医薬、食品等に用いられる物質、具体的には例えば、ビ
タミンＡ、Ｅ、Ｄなどの脂溶性ビタミン類およびそれら
の誘導体、ＣｏＱ8、ＣｏＱ10などのコエンザイム類、
ショウキョウ油、チョウジ油、ケイヒ油などの精油類、
大豆油、サフラワー油、コーン油、ゴマ油、オリーブ油
などの植物油などを配合する事もできる。Further, in the present invention, a substance used in fat-soluble medicines, foods, etc. in the emulsion, specifically, for example, fat-soluble vitamins such as vitamins A, E and D and their derivatives, CoQ 8 , CoQ 10 and other coenzymes,
Essential oils such as ginger oil, clove oil, cinnamon oil,
Vegetable oils such as soybean oil, safflower oil, corn oil, sesame oil, olive oil and the like can also be added.
【００１５】本発明の液剤には、エタノール、グリセリ
ン、プロピレングリコールなどの多価アルコール類、ソ
ルビトール、マルチトール、キシリトール、エリスリト
ールなどの糖アルコール類、ビタミンＢ2、Ｂ6、パント
テン酸などの水溶性ビタミン類、タウリン、コンドロイ
チン硫酸ナトリウム、カフェイン、生薬エキス、矯味
剤、香料、着色料、保存料などビタミンＣの安定性に影
響しない成分を配合することもできる。The liquid preparation of the present invention includes polyhydric alcohols such as ethanol, glycerin and propylene glycol, sugar alcohols such as sorbitol, maltitol, xylitol and erythritol, water-soluble vitamins B 2 , B 6 and pantothenic acid. Ingredients that do not affect the stability of vitamin C, such as vitamins, taurine, sodium chondroitin sulfate, caffeine, herbal extracts, flavoring agents, flavoring agents, coloring agents and preservatives, can also be added.
【００１６】[0016]
【発明の効果】後記試験例から明らかなように、本発明
により酸性条件下においても液剤中のビタミンＣを長期
間安定化することができたので、ビタミンＣを配合した
風味のよいドリンク剤、ビタミンＣを配合したローショ
ン剤などを提供することが可能になった。EFFECTS OF THE INVENTION As is apparent from the test examples described below, the present invention was able to stabilize vitamin C in a liquid formulation for a long period of time even under acidic conditions. Therefore, a flavorful drink formulation containing vitamin C, It has become possible to provide lotions and the like containing vitamin C.
【００１７】[0017]
【実施例】以下に実施例および試験例により更に詳細に
説明する。EXAMPLES The present invention will be described in more detail below with reference to examples and test examples.
【００１８】実施例１
ビタミンＥ酢酸エステル１０ｇ、ショ糖ステアリン酸エ
ステル１２ｇ、大豆レシチン５ｇを２０ｍｌのエタノー
ルに加え、６０℃で溶解させた。この溶液を１リットル
の水に添加し、オートホモミキサー（特殊機化工業製）
を用い、８０００ｒｐｍで５分間室温で撹拌し、乳化物
を得た。Example 1 10 g of vitamin E acetate, 12 g of sucrose stearate and 5 g of soybean lecithin were added to 20 ml of ethanol and dissolved at 60 ° C. This solution was added to 1 liter of water, and an auto homomixer (made by Tokushu Kika Kogyo)
Was stirred at 8000 rpm for 5 minutes at room temperature to obtain an emulsion.
【００１９】ここで得られた乳化物１０ｍｌにアスコル
ビン酸０．６ｇを加え、さらに矯味剤としてグリセリン
５ｇおよびマルチトール６ｇを加え、水を加え５０ｍｌ
とした。この水溶液にクエン酸ナトリウムを加えｐＨを
４．０および５．０の２つのサンプルに調整した。ま
た、保存剤として安息香酸ナトリウムおよびエチルパラ
ベンを適量配合した。0.6 g of ascorbic acid was added to 10 ml of the emulsion thus obtained, 5 g of glycerin and 6 g of maltitol were added as a corrigent, and 50 ml of water was added.
And Sodium citrate was added to this aqueous solution to adjust the pH to two samples of 4.0 and 5.0. In addition, sodium benzoate and ethylparaben were mixed in appropriate amounts as preservatives.
【００２０】比較例１
実施例１と同じビタミンＣ濃度およびｐＨにして、０．
１Ｍクエン酸緩衝溶液を調製した。Comparative Example 1 The same vitamin C concentration and pH as in Example 1 were used, and
A 1M citrate buffer solution was prepared.
【００２１】比較例２
実施例１からショ糖脂肪酸エステルを除いた処方で実施
例１と同様の方法によりｐＨ４．０および５．０の２つ
のサンプルを調製した。Comparative Example 2 Two samples having pH 4.0 and 5.0 were prepared by the same method as in Example 1 except that the sucrose fatty acid ester was removed from Example 1.
【００２２】試験例１
ビタミンＣの定量は高速液体クロマトグラフィー（ＨＰ
ＬＣ）により行った。ＨＰＬＣは日立製作所製のＬ−６
０００シリーズ、カラムはＴＯＳＯ製のＯＤＳ−８０Ｔ
ｓ（製品名）を用い、逆相にて定量した。検出には、Ｕ
Ｖ（紫外線）検出器を用い、２５４ｎｍで検出した。Test Example 1 Vitamin C was quantified by high performance liquid chromatography (HP
LC). HPLC is L-6 manufactured by Hitachi Ltd.
000 series, column is TODS ODS-80T
s (product name) was used for quantification in reverse phase. U for detection
Detection was performed at 254 nm using a V (ultraviolet) detector.
【００２３】実施例および比較例の４０℃および５０℃
におけるビタミンＣ残存率の経時変化の結果を表１に示
した。40 ° C. and 50 ° C. of Examples and Comparative Examples
Table 1 shows the results of the time-dependent changes in the residual rate of vitamin C in.
【００２４】[0024]
【表１】 [Table 1]
───────────────────────────────────────────────────── フロントページの続き (72)発明者 長濱 徹 東京都豊島区高田３丁目24番１号 大正 製薬株式会社内 (56)参考文献 特開 昭57−14587（ＪＰ，Ａ) 特許173274（ＪＰ，Ｃ２) (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 31/375 A61K 9/08 A61K 47/24 A61K 47/26 ＣＡ（ＳＴＮ) ＲＥＧＩＳＴＲＹ（ＳＴＮ)─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Toru Nagahama 3-24-1 Takada, Toshima-ku, Tokyo Within Taisho Pharmaceutical Co., Ltd. (56) Reference JP-A-57-14587 (JP, A) Patent 173274 (JP) , C2) (58) Fields surveyed (Int.Cl. 7 , DB name) A61K 31/375 A61K 9/08 A61K 47/24 A61K 47/26 CA (STN) REGISTRY (STN)
Claims (4)
て、ショ糖脂肪酸エステル、乳化剤としてリン脂質を配
合して得られた乳化物を配合することを特徴とする液
剤。1. A acidic solution containing a combination of vitamin C, a solution which is characterized in blending the emulsion obtained by blending the phospholipid tio sugar fatty acid ester, as an emulsifier.
チンである請求項１記載の液剤。2. The liquid preparation according to claim 1, wherein the phospholipid is egg yolk lecithin or soybean lecithin.
たは２記載の液剤。3. The liquid agent according to claim 1, which has a pH of 2.0 to 5.0.
ョ糖脂肪酸エステル、乳化剤としてリン脂質を配合して
得られた乳化物を配合することを特徴とする、ビタミン
Ｃの安定化方法。4. A liquid containing a combination of vitamin C, characterized by blending the emulsion obtained by blending a phospholipid <br/> tio sugar fatty acid ester, as an emulsifier, stabilizer vitamin C Method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21069395A JP3508314B2 (en) | 1995-08-18 | 1995-08-18 | Liquid formulation containing vitamin C |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21069395A JP3508314B2 (en) | 1995-08-18 | 1995-08-18 | Liquid formulation containing vitamin C |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0959145A JPH0959145A (en) | 1997-03-04 |
| JP3508314B2 true JP3508314B2 (en) | 2004-03-22 |
Family
ID=16593545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21069395A Expired - Fee Related JP3508314B2 (en) | 1995-08-18 | 1995-08-18 | Liquid formulation containing vitamin C |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3508314B2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4064493B2 (en) * | 1997-04-25 | 2008-03-19 | あすか製薬株式会社 | Vitamins containing composition |
| US6132737A (en) * | 1997-09-29 | 2000-10-17 | Revlon Consumer Products Corporation | Method for reducing sunburn cell formation with cosmetic compositions containing ascorbic acid |
| TW592713B (en) * | 1998-05-11 | 2004-06-21 | Ciba Sc Holding Ag | Use of nanodispersions in cosmetic end formulations |
| TWI241915B (en) * | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
| US8080097B2 (en) * | 2003-11-06 | 2011-12-20 | Hewlett-Packard Development Company, L.P. | System and a method for the creation of edible, optically invisible images |
| IL191123A0 (en) * | 2008-04-28 | 2009-02-11 | Meir Shinitzky | Composition comprising phospholipids in combination with ascorbic acid and cosmetic products comprising it |
| CN106345365B (en) * | 2011-05-10 | 2021-05-28 | 阿彻丹尼尔斯米德兰德公司 | Dispersants with biobased compounds |
| JP6676282B2 (en) * | 2014-03-26 | 2020-04-08 | 武田薬品工業株式会社 | Vitamin C containing solution |
-
1995
- 1995-08-18 JP JP21069395A patent/JP3508314B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0959145A (en) | 1997-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0325244B1 (en) | Aqueous solution of fat-soluble substance | |
| JPH049768B2 (en) | ||
| AU2007305614B2 (en) | O/W/O emulsion containing lignan compounds and composition containing the same | |
| US10888572B2 (en) | Dietary and nutritional compositions and methods of use | |
| EP1864659B1 (en) | Lignane compound-containing oil-in-water emulsion and composition comprising the same | |
| JP2551755B2 (en) | Method for producing solubilized liquid | |
| JP4304940B2 (en) | Propolis extract-containing composition for water dispersion and beverage | |
| KR19990063669A (en) | New way | |
| JP2008231117A (en) | Fat emulsion containing xanthine derivative | |
| JP3833648B2 (en) | Water-soluble composition containing coenzyme Q10 | |
| JP3508314B2 (en) | Liquid formulation containing vitamin C | |
| JPWO2019066068A1 (en) | Oil-in-water emulsion composition, and food and beverage containing the same | |
| JP2002514394A (en) | Use of nanofoods in human and animal food end products | |
| JPH0693996B2 (en) | Emulsified composition | |
| JPH047722B2 (en) | ||
| JP2006306879A (en) | Method for producing water-soluble composition containing coenzyme Q10 | |
| JP2976162B2 (en) | Stable multivitamin oral solution | |
| JP2002193825A (en) | Liquid composition | |
| JP3192234B2 (en) | External preparation for skin | |
| JP2950348B2 (en) | Fat emulsion and method for producing the same | |
| JP2004175664A (en) | Aqueous composition of fat-soluble vitamins, production method and administration method | |
| JP2940249B2 (en) | Infusion preparation | |
| KR100786884B1 (en) | Coenzyme 90-containing water-soluble composition | |
| JP2003160477A (en) | Aqueous composition of higher aliphatic alcohols, method of manufacture and method of administration | |
| JP2002128672A (en) | Solubilized liquid composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20031215 |
|
| LAPS | Cancellation because of no payment of annual fees |